MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression

[1]  I. Díaz-Padilla.  Ovarian Cancer - A Clinical and Translational Update , 2013 .

[2]  C. Rancourt,et al.  Biological Significance of Apoptosis in Ovarian Cancer: TRAIL Therapeutic Targeting , 2013 .

[3]  C. Rancourt,et al.  The Role of MUC16 Mucin (CA125) in the Pathogenesis of Ovarian Cancer , 2012 .

[4]  S. Farghaly.  Ovarian Cancer - Basic Science Perspective , 2012 .

[5]  S. Batra,et al.  MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells , 2012, Oncogene.

[6]  C. Rancourt,et al.  Targeted ovarian cancer treatment: the TRAILs of resistance. , 2012, American journal of cancer research.

[7]  Maxime Pinard,et al.  MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. , 2011, Gynecologic oncology.

[8]  C. Rancourt,et al.  Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes , 2010, Molecular Cancer.

[9]  S. Canevari,et al.  Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. , 2010, The international journal of biochemistry & cell biology.

[10]  C. Rancourt,et al.  MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells , 2010, Molecular Cancer.

[11]  C. Rancourt,et al.  CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. , 2009, Gynecologic oncology.

[12]  F. Mantelli,et al.  Association of Cell Surface Mucins with Galectin-3 Contributes to the Ocular Surface Epithelial Barrier* , 2009, The Journal of Biological Chemistry.

[13]  B. Zhivotovsky,et al.  Mitochondrial targeting of tBid/Bax: a role for the TOM complex? , 2009, Cell Death and Differentiation.

[14]  Mitchell Ho,et al.  A Binding Domain on Mesothelin for CA125/MUC16* , 2009, Journal of Biological Chemistry.

[15]  D. Kufe,et al.  MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. , 2008, Cancer research.

[16]  A. Ashkenazi,et al.  Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  I. Jacobs,et al.  CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. , 2007, Gynecologic oncology.

[18]  Mitchell Ho,et al.  Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors , 2006, Molecular Cancer.

[19]  A. Piché,et al.  Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3 , 2006, Molecular Cancer Therapeutics.

[20]  A. Piché,et al.  Bcl-XL is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells , 2006 .

[21]  A. Piché,et al.  Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells. , 2006, Gynecologic oncology.

[22]  C. Rancourt,et al.  Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. , 2004, Gynecologic oncology.

[23]  N. Umesaki,et al.  Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion* , 2004, Journal of Biological Chemistry.

[24]  D. Kufe,et al.  Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. , 2004, Cancer cell.

[25]  J. Meza,et al.  Inhibition of MUC4 Expression Suppresses Pancreatic Tumor Cell Growth and Metastasis , 2004, Cancer Research.

[26]  P. Scheurich,et al.  TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy , 2002, Apoptosis.

[27]  W. El-Deiry,et al.  Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.

[28]  K. Shigemasa,et al.  The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure , 2002, Tumor Biology.

[29]  B. Yin,et al.  Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene , 2002, International journal of cancer.

[30]  M. Hollingsworth,et al.  Overexpression of MUC1 reconfigures the binding properties of tumor cells , 2001, International journal of cancer.

[31]  P. Krammer,et al.  FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis , 2001, Molecular and Cellular Biology.

[32]  T. O'brien,et al.  The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences , 2001, Tumor Biology.

[33]  B. Yin,et al.  Molecular Cloning of the CA125 Ovarian Cancer Antigen , 2001, The Journal of Biological Chemistry.

[34]  Masanobu Komatsu,et al.  Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor , 2001, Oncogene.

[35]  M. Hollingsworth,et al.  Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti‐adhesion molecule , 2000, International journal of cancer.

[36]  D. Lawrence,et al.  Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.

[37]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[39]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[40]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[41]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[42]  R. Dubose,et al.  Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.

[43]  M. Peter,et al.  Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.

[44]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[45]  M. Ligtenberg,et al.  Cell membrane-associated mucins and their adhesion-modulating property. , 1992, Trends in biochemical sciences.

[46]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[47]  R. Bast,et al.  Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. , 1983, American journal of clinical pathology.